UBS Group assumed coverage on shares of Bio-Rad Laboratories (NYSE:BIO – Free Report) in a report released on Thursday, Marketbeat reports. The brokerage issued a buy rating and a $395.00 price objective on the medical research company’s stock. Separately, StockNews.com cut Bio-Rad Laboratories from a buy rating to a hold rating in a report on […]
UBS Group started coverage on shares of Bio-Rad Laboratories (NYSE:BIO – Free Report) in a research note published on Thursday, MarketBeat.com reports. The brokerage issued a buy rating and a $395.00 price target on the medical research company’s stock. Separately, StockNews.com lowered shares of Bio-Rad Laboratories from a buy rating to a hold rating in […]
Analysts at UBS Group assumed coverage on shares of Bio-Rad Laboratories (NYSE:BIO – Get Free Report) in a note issued to investors on Thursday, Briefing.com reports. The firm set a “buy” rating and a $395.00 price target on the medical research company’s stock. UBS Group’s price target would suggest a potential upside of 27.12% from […]
Platinum Investment Management Ltd. lessened its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 52.9% during the second quarter, Holdings Channel reports. The firm owned 8,636 shares of the medical research company’s stock after selling 9,706 shares during the quarter. Platinum Investment Management Ltd.’s holdings in Bio-Rad Laboratories were worth $3,274,000 […]
Thompson Siegel & Walmsley LLC boosted its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 44.8% during the second quarter, Holdings Channel.com reports. The firm owned 294,164 shares of the medical research company’s stock after buying an additional 91,013 shares during the quarter. Bio-Rad Laboratories makes up approximately 1.8% of Thompson […]